WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke YAVEMBO wurde als Wortmarke am 27.04.2022 bei der Weltorganisation für geistiges Eigentum angemeldet.
| Markenform | Wortmarke |
| Aktenzeichen | 1674098 |
| Registernummer | 619292 |
| Länder | 
|
| Basismarke |
Nr. 619292,
27. Dezember 2021
|
| Anmeldedatum | 27. April 2022 |
| Ablaufdatum | 27. April 2032 |
Markeninhaber
Ideon Science Park
223 70 Lund
SE
223 70 Lund
SE
Markenvertreter
Box 5117
200 71 MALMÖ
SE
Waren und Dienstleistungen
05
Pharmaceutical preparations; pharmaceutical preparations for
injection; pharmaceutical preparation for subcutaneous
injection; pharmaceutical preparations for the treatment of
endocrine diseases and disorders; pharmaceutical
preparations for the treatment of tumours; pharmaceutical
preparations for the treatment of carcinoid tumours;
pharmaceutical preparations comprising peptides for hormonal
treatment and tumour treatment; pharmaceutical preparations
for the treatment of neuroendocrine tumours; pharmaceutical
preparations for the treatment of gastro-enteropancreatic
neuroendocrine tumours; pharmaceutical preparations for the
treatment of gastrointestinal diseases and disorders;
pharmaceutical preparations for gastrointestinal bleeding
disorders; pharmaceutical preparations for the treatment of
gastrointestinal bleeding disorders; pharmaceutical
preparations for the treatment of esophageal bleeding;
pharmaceutical preparations for metabolic disorders;
pharmaceutical preparations for the treatment of acromegaly;
pharmaceutical preparations for the treatment of polycystic
liver disease; pharmaceutical preparations for the treatment
of respiratory diseases or syndrome; pharmaceutical
preparations for the treatment of respiratory distress
syndrome; pharmaceutical preparations for the treatment of
acute respiratory distress syndrome; pharmaceutical
preparations for the treatment of disorders of the autonomic
nervous system; pharmaceutical preparations intended to
block growth hormone
10
Devices for administration of pharmaceuticals for the
treatment of endocrine diseases and disorders; devices for
administration of pharmaceuticals for the treatment of
tumours; devices for administration of pharmaceuticals for
the treatment of carcinoid tumours; devices for
administration of pharmaceuticals comprising peptides for
hormonal treatment and tumour treatment; devices for
administration of pharmaceuticals for the treatment of
neuroendocrine tumours; devices for administration of
pharmaceuticals for the treatment of gastro-enteropancreatic
neuroendocrine tumours; devices for administration of
pharmaceuticals for the treatment of gastrointestinal
diseases and disorders; devices for administration of
pharmaceuticals for gastrointestinal bleeding disorders;
devices for administration of pharmaceuticals for the
treatment of gastrointestinal bleeding disorders; devices
for administration of pharmaceuticals for the treatment of
esophageal bleeding; devices for administration of
pharmaceuticals for metabolic disorders; devices for
administration of pharmaceuticals for the treatment of
acromegaly; devices for administration of pharmaceuticals
for the treatment of polycystic liver disease; devices for
administration of pharmaceuticals for the treatment of
respiratory diseases or syndrome; devices for administration
of pharmaceuticals for the treatment of respiratory distress
syndrome; devices for administration of pharmaceuticals for
the treatment of acute respiratory distress syndrome;
devices for administration of pharmaceuticals for the
treatment of disorders of the autonomic nervous system;
devices for administration of pharmaceuticals intended to
block growth hormone; syringes for administration of
pharmaceuticals for the treatment of endocrine diseases and
disorders; syringes for administration of pharmaceuticals
for the treatment of tumours; syringes for administration of
pharmaceuticals for the treatment of carcinoid tumours;
syringes for administration of pharmaceuticals comprising
peptides for hormonal treatment and tumour treatment;
syringes for administration of pharmaceuticals for the
treatment of neuroendocrine tumours; syringes for
administration of pharmaceuticals for the treatment of
gastro-enteropancreatic neuroendocrine tumours; syringes for
administration of pharmaceuticals for the treatment of
gastrointestinal diseases and disorders; syringes for
administration of pharmaceuticals for gastrointestinal
bleeding disorders; syringes for administration of
pharmaceuticals for the treatment of gastrointestinal
bleeding disorders; syringes for administration of
pharmaceuticals for the treatment of esophageal bleeding;
syringes for administration of pharmaceuticals for metabolic
disorders; syringes for administration of pharmaceuticals
for the treatment of acromegaly; syringes for administration
of pharmaceuticals for the treatment of polycystic liver
disease; syringes for administration of pharmaceuticals for
the treatment of respiratory diseases or syndrome; syringes
for administration of pharmaceuticals for the treatment of
respiratory distress syndrome; syringes for administration
of pharmaceuticals for the treatment of acute respiratory
distress syndrome; syringes for administration of
pharmaceuticals for the treatment of disorders of the
autonomic nervous system; syringes for administration of
pharmaceuticals intended to block growth hormone; pens for
administration of pharmaceuticals for the treatment of
endocrine diseases and disorders; pens for administration of
pharmaceuticals for the treatment of tumours; pens for
administration of pharmaceuticals for the treatment of
carcinoid tumours; pens for administration of
pharmaceuticals comprising peptides for hormonal treatment
and tumour treatment; pens for administration of
pharmaceuticals for the treatment of neuroendocrine tumours;
pens for administration of pharmaceuticals for the treatment
of gastro-enteropancreatic neuroendocrine tumours; pens for
administration of pharmaceuticals for the treatment of
gastrointestinal diseases and disorders; pens for
administration of pharmaceuticals for gastrointestinal
bleeding disorders; pens for administration of
pharmaceuticals for the treatment of gastrointestinal
bleeding disorders; pens for administration of
pharmaceuticals for the treatment of esophageal bleeding;
pens for administration of pharmaceuticals for metabolic
disorders; pens for administration of pharmaceuticals for
the treatment of acromegaly; pens for administration of
pharmaceuticals for the treatment of polycystic liver
disease; pens for administration of pharmaceuticals for the
treatment of respiratory diseases or syndrome; pens for
administration of pharmaceuticals for the treatment of
respiratory distress syndrome; pens for administration of
pharmaceuticals for the treatment of acute respiratory
distress syndrome; pens for administration of
pharmaceuticals for the treatment of disorders of the
autonomic nervous system; pens for administration of
pharmaceuticals intended to block growth hormone; devices
for subcutaneous administration of pharmaceuticals; devices
for parenteral administration of pharmaceuticals; devices
for injection of pharmaceutical depots; devices for
subcutaneous injection of pharmaceutical depot; devices for
parenteral injection of pharmaceutical depot; devices for
injection of injection fluids; devices for injection of
injection depot; devices for subcutaneous administration of
pharmaceuticals; devices for parenteral administration of
pharmaceuticals; syringes for subcutaneous administration of
pharmaceuticals; syringes for parenteral administration of
pharmaceuticals; syringes for injection of pharmaceutical
depots; syringes for subcutaneous injection of
pharmaceutical depot; syringes for parenteral injection of
pharmaceutical depot; syringes for injection of injection
fluids; syringes for injection of injection depot; syringes
for injections; syringes for medical uses; pens for
subcutaneous administration of pharmaceuticals; pens for
parenteral administration of pharmaceuticals; pens for
injection of pharmaceutical depots; pens for subcutaneous
injection of pharmaceutical depot; pens for parenteral
injection of pharmaceutical depot; pens for injection of
injection fluids; pens for injection of injection depot;
pens for injections; pens for medical uses
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 07. August 2023 | 2023/32 Gaz | MX | Ablehnung |
| 07. Juli 2023 | 2023/28 Gaz | LI | Ablehnung |
| 22. Juni 2023 | 2023/25 Gaz | NO | Ablehnung |
| 13. Juni 2023 | 2023/24 Gaz | CH | Ablehnung |
| 18. Mai 2023 | 2023/20 Gaz | JP | Ablehnung |
| 17. Mai 2023 | 2023/21 Gaz | BR | Ablehnung |
| 10. Mai 2023 | 2023/19 Gaz | UA | Ablehnung |
| 05. April 2023 | 2023/14 Gaz | US | Ablehnung |
| 16. Februar 2023 | 2023/7 Gaz | CN | Ablehnung |
| 10. Februar 2023 | 2023/7 Gaz | SM | Ablehnung |
| 31. Januar 2023 | 2023/5 Gaz | NZ | Ablehnung |
| 11. Januar 2023 | 2023/2 Gaz | RU | Ablehnung |
| 20. Dezember 2022 | 2022/51 Gaz | TR | Ablehnung |
| 12. Dezember 2022 | 2022/52 Gaz | IL | Ablehnung |
| 08. Dezember 2022 | 2022/49 Gaz | EM | Ablehnung |
| 12. Oktober 2022 | 2022/41 Gaz | GB | Ablehnung |
| 30. September 2022 | 2022/39 Gaz | AU | Ablehnung |
| 21. September 2022 | 2022/38 Gaz | MC | Ablehnung |
| 27. April 2022 | 2022/27 Gaz | SE | Eintragung |
ID: 141674098